Chawla Neal S, Sayegh Nicolas, Prajapati Sweta, Chan Elyse, Pal Sumanta K, Chehrazi-Raffle Alexander
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Cancers (Basel). 2023 Jan 17;15(3):565. doi: 10.3390/cancers15030565.
Papillary renal cell carcinoma (pRCC) is the second-most common subtype of kidney cancer following clear cell renal cell carcinoma (ccRCC), representing 15% of kidney cancers. Despite advances in therapy, including combination strategies with targeted therapies and immune checkpoint inhibitors, progress has lagged behind that of ccRCC. This is in part due to the heterogenous nature of the various subtypes of pRCC. More recently, investigators have turned efforts towards histology and biology-based trials. In this review, we outline some of the distinct biological characteristics of pRCC and discuss the most impactful clinical trials to date. Finally, we look ahead to several highly anticipated ongoing trials in pRCC.
乳头状肾细胞癌（pRCC）是继透明细胞肾细胞癌（ccRCC）之后第二常见的肾癌亚型，占肾癌的15%。尽管在治疗方面取得了进展，包括靶向治疗和免疫检查点抑制剂的联合策略，但进展仍落后于ccRCC。这部分是由于pRCC各亚型的异质性。最近，研究人员已将努力转向基于组织学和生物学的试验。在本综述中，我们概述了pRCC的一些独特生物学特征，并讨论了迄今为止最具影响力的临床试验。最后，我们展望了pRCC中几项备受期待的正在进行的试验。
Zotero 插件